Davenport & Co
IRMD icon

Davenport & Co’s iRadimed IRMD Stock Holding History

Davenport & Co’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$210K Sell
2,435
-350
-13% -$31.4K ﹤0.01% 1329
2026
Q2 		$266K Hold
2,785
– – ﹤0.01% 1231
2026
Q1 		$268K Buy
2,785
+385
+16% +$38.5K ﹤0.01% 1181
2025
Q4 		$233K Buy
+2,400
New +$206K ﹤0.01% 1174

Other funds holding IRMD

Copeland Capital Management
Copeland Capital Management Conshohocken, Pennsylvania $4.34B AUM 17.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Ranger Investment Management
Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return
Bridge City Capital
Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return
Shaker Investments
Shaker Investments Cleveland, Ohio $268M AUM 52.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Davenport & Co's IRMD Position: Q3 2026 in Review

Davenport & Co reduced its iRadimed (IRMD) stake by 13% in Q3 2026, selling an estimated $31.4K and leaving 2,435 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #1329.

Davenport & Co first reported a position in IRMD in Q4 2025 and has held it in 4 quarters since. The position peaked at $268K in Q1 2026. 98 funds tracked by Wall St. Rank hold IRMD as of Q3 2026.

  • Davenport & Co held 2,435 shares of iRadimed worth $210K as of Q3 2026.
  • Davenport & Co sold 350 iRadimed shares in Q3 2026, an estimated $31.4K.
  • iRadimed made up ﹤0.01% of Davenport & Co's portfolio in Q3 2026, its #1329 holding.
  • Davenport & Co first reported a position in iRadimed in Q4 2025 and has held it in 4 quarters since.
  • Davenport & Co's iRadimed position peaked at $268K in Q1 2026.
  • 98 funds tracked by Wall St. Rank held iRadimed as of Q3 2026.

Based on Davenport & Co's 13F filing for Q3 2026, filed 14 Oct 2026.